Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US07725L1026
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG00B6WF7T5
ONC
BeOne Medicines Ltd.
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: - · THEMEFOLIO: $HLTH
NAME
BeOne Medicines Ltd.
ISIN
US07725L1026
TICKER
ONC
MIC
XNAS
REUTERS
ONC.OQ
BLOOMBERG
ONC US
Wed, 05.08.2026       BeOne Medicines
US07725L1026

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the second quarter of 2026. John V. Oyler, Co-Founder, Chairman, and CEO, BeOne, said: “These strong second-quarter results underscore our continued growth as a global oncology leader. Our founda...
Read more
BeOne Medicines
Technical Analysis Termsheets Terminal
Permalink
Thu, 23.07.2026       BeOne Medicines
US07725L1026

BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a $300 million expansion of its flagship clinical and commercial-stage manufacturing and research and development center at the Princeton West Innovation Campus in Hopewell, New Jersey, bringing total U.S. manufacturing investment to more than...
Read more
BeOne Medicines
Technical Analysis Termsheets Terminal
Permalink
Fri, 17.07.2026       BeOne Medicines
US07725L1026

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its second quarter 2026 financial results on Wednesday, August 5, 2026 before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET. The live webcast of this even...
Read more
BeOne Medicines
Technical Analysis Termsheets Terminal
Permalink
Tue, 30.06.2026       BeOne Medicines
US07725L1026

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the Phase 3 MANGROVE study (BGB-3111-306; NCT04002297) evaluating foundational BTK inhibitor BRUKINSA® (zanubrutinib) plus rituximab versus bendamustine plus rituximab (BR) in adult patients with previously untreat...
Read more
BeOne Medicines
Technical Analysis Termsheets Terminal
Permalink
Fri, 12.06.2026       BeOne Medicines
US07725L1026

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association (EHA) Congress in Stockholm. Updated results from tacabrutideg (BGB-16673), a potential best-in-class Bruton’s tyrosine kinase (BTK) degrader, demon...
Read more
BeOne Medicines
Technical Analysis Termsheets Terminal
Permalink
Thu, 11.06.2026       BeOne Medicines
US07725L1026

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of a large Phase 3 dataset in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) aged 80 and older, showing sustained benefit with BRUKINSA after nearly 6.5 years of follow-up, reinforcing its ro...
Read more
BeOne Medicines
Technical Analysis Termsheets Terminal
Permalink
Mon, 01.06.2026       BeOne Medicines
US07725L1026

BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its solid tumor pipeline being presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29–June 2, Chicago). These data underscore the significant acceleration across the Company’s high-prio...
Read more
BeOne Medicines
Technical Analysis Termsheets Terminal
Permalink
Fri, 29.05.2026       BeOne Medicines
US07725L1026

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foun...
Read more
BeOne Medicines
Technical Analysis Termsheets Terminal
Permalink
Wed, 27.05.2026       BeOne Medicines
US07725L1026

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that data from HERIZON-GEA-01 were published in The New England Journal of Medicine and will be presented in an oral presentation (Rapid Oral Abstract: 4010) at the American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2026, in...
Read more
BeOne Medicines
Technical Analysis Termsheets Terminal
Permalink
Tue, 26.05.2026       BeOne Medicines
US07725L1026

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026, with a fireside chat at 10:00 a.m. EDT. The live webcast of this event can be accessed from the investors section of the Company’s website at h...
Read more
BeOne Medicines
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Thu, 21.05.2026       BeOne Medicines
US07725L1026

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that more than 60 abstracts across hematologic malignancies and solid tumors have been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29–June 2, Chicago) and the 2026 European Hematology A...
Read more
BeOne Medicines
Technical Analysis Termsheets Terminal
Permalink
Wed, 20.05.2026       BeOne Medicines
US07725L1026

BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today launched One Save Changes Everything, a campaign that uses soccer as a lens to recognize the scientific, clinical, and human moments that matter in cancer care. The campaign launches with goalkeeping legends, including former U.S. Men’s Nationa...
Read more
BeOne Medicines
Technical Analysis Termsheets Terminal
Permalink
Wed, 13.05.2026       BeOne Medicines
US07725L1026

BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to BEQALZI™ (bee-KAHL-zee; sonrotoclax), a foundational, next-generation BCL2 inhibitor, for the treatment of adult patients with relapsed or refractory...
Read more
BeOne Medicines
Technical Analysis Termsheets Terminal
Permalink
Wed, 06.05.2026       BeOne Medicines
US07725L1026

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the first quarter of 2026. John V. Oyler, Co-Founder, Chairman, and CEO, BeOne, said: “These strong first-quarter results reinforce BeOne’s continued growth as a global oncology leader, driven by...
Read more
BeOne Medicines
Technical Analysis Termsheets Terminal
Permalink
Wed, 29.04.2026       BeOne Medicines
US07725L1026

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line trea...
Read more
BeOne Medicines
Technical Analysis Termsheets Terminal
Permalink
Wed, 22.04.2026       BeOne Medicines
US07725L1026

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its first quarter 2026 financial results on Wednesday, May 6, 2026 before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET. The live webcast of this event ca...
Read more
BeOne Medicines
Technical Analysis Termsheets Terminal
Permalink
Thu, 26.02.2026       BeOne Medicines
US07725L1026

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the fourth quarter and full year 2025. “These strong financial results for the fourth quarter and full year 2025 underscore our continued evolution as a global oncology leader with durable competit...
Read more
BeOne Medicines
Technical Analysis Termsheets Terminal
Permalink
Tue, 17.02.2026       BeOne Medicines
US07725L1026

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Company will participate in fireside chats at four upcoming investor conferences: TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at 9:10 am ET; Leerink Global Healthcare Conference on Monday, March 9, 2026 a...
Read more
BeOne Medicines
Technical Analysis Termsheets Terminal
Permalink
Wed, 11.02.2026       BeOne Medicines
US07725L1026

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its fourth quarter and full year 2025 financial results on Thursday, February 26, 2026 before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET. The live webc...
Read more
BeOne Medicines
Technical Analysis Termsheets Terminal
Permalink
Tue, 13.01.2026       BeOne Medicines
US07725L1026

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will outline the pillars of its growing global oncology leadership during its presentation today at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. John V. Oyler, Co-Founder, Chairman, and CEO at BeOne, will highlight the Company’s transf...
Read more
BeOne Medicines
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Tue, 06.01.2026       BeOne Medicines
US07725L1026

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced full results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with and without PD-1 inhibitor TEVIMBRA® (tislelizumab), as a first-line treatment for...
Read more
BeOne Medicines
Technical Analysis Termsheets Terminal
Permalink
Tue, 23.12.2025       BeOne Medicines
US07725L1026

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, with a presentation at 7:30 am PST. Live webcasts of these events can be accessed from the investors section of the Company’s website at ht...
Read more
BeOne Medicines
Technical Analysis Termsheets Terminal
Permalink
Thu, 18.12.2025       BeOne Medicines
US07725L1026

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company Fast Track Designation for BGB-B2033, its GPC3x4-1BB bispecific antibody for the treatment of adult patients with hepatocellular carcinoma (HCC) with disease progression o...
Read more
BeOne Medicines
Technical Analysis Termsheets Terminal
Permalink
Mon, 08.12.2025       BeOne Medicines
US07725L1026

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, reaffirms its position as the leader in chronic lymphocytic leukemia (CLL) innovation by showcasing the depth, quality, and momentum of its hematology portfolio at the 67th ASH Annual Meeting and Exposition in Orlando, Florida. The totality of BeOne’s ASH data...
Read more
BeOne Medicines
Technical Analysis Termsheets Terminal
Permalink
Mon, 08.12.2025       BeOne Medicines
US07725L1026

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematolo...
Read more
BeOne Medicines
Technical Analysis Termsheets Terminal
Permalink
Wed, 26.11.2025       BeOne Medicines
US07725L1026

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to a New Drug Application (NDA) for sonrotoclax, a next-generation BCL2 inhibitor, for the treatment of adult patients with relapsed or refractory (R/R) m...
Read more
BeOne Medicines
Technical Analysis Termsheets Terminal
Permalink
Thu, 20.11.2025       BeOne Medicines
US07725L1026

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, advances its vision to become the world’s leading oncology company with extensive new data from its differentiated hematology portfolio at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, Florida, December 6-9. Nearly 50...
Read more
BeOne Medicines
Technical Analysis Termsheets Terminal
Permalink
Mon, 17.11.2025       BeOne Medicines
US07725L1026

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive top-line results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with or without PD-1 inhibitor TEVIMBRA® (tislelizumab), as first-line tre...
Read more
BeOne Medicines
Technical Analysis Termsheets Terminal
Permalink
Thu, 06.11.2025       BeOne Medicines
US07725L1026

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the third quarter of 2025. “These strong financial results reinforce our position as a global oncology leader with exceptional topline growth and a strong balance sheet,” said John V. Oyler, Co-Foun...
Read more
BeOne Medicines
Technical Analysis Termsheets Terminal
Permalink
Tue, 28.10.2025       BeOne Medicines
US07725L1026

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in fireside chats at two upcoming investor conferences: Guggenheim Second Annual Healthcare Innovation Conference on Monday, November 10, 2025 at 9:30 am EST; and Jefferies Global Healthcare Conference in London on Mon...
Read more
BeOne Medicines
Technical Analysis Termsheets Terminal
Permalink
Wed, 22.10.2025       BeOne Medicines
US07725L1026

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its third quarter 2025 financial results on Thursday, November 6, 2025 before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET. The live webcast of this even...
Read more
BeOne Medicines
Technical Analysis Termsheets Terminal
Permalink
Mon, 20.10.2025       BeOne Medicines
US07725L1026

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of data from two pivotal Phase 3 trials – RATIONALE-307 and 312 – offering new evidence of the benefits of its PD-1 inhibitor, TEVIMBRA® (tislelizumab), at the European Society of Medical Oncology 2025 Congress (ESMO 2025) in B...
Read more
BeOne Medicines
Technical Analysis Termsheets Terminal
Permalink
Mon, 13.10.2025       BeOne Medicines
US07725L1026

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for sonrotoclax, a next-generation and potentially best-in-class investigational BCL2 inhibitor, for the treatment of adult patients with relaps...
Read more
BeOne Medicines
Technical Analysis Termsheets Terminal
Permalink
Fri, 29.08.2025       BeOne Medicines
US07725L1026

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from a Phase 1/2 study (BGB-11417-201) of sonrotoclax, a next-generation and potentially best-in-class investigational BCL2 inhibitor, in adult patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), followi...
Read more
BeOne Medicines
Technical Analysis Termsheets Terminal
Permalink
Wed, 27.08.2025       BeOne Medicines
US07725L1026

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Commission (EC) has approved TEVIMBRA (tislelizumab), in combination with platinum-containing chemotherapy as neoadjuvant treatment followed by TEVIMBRA monotherapy as adjuvant treatment, for adult patients with resectable non...
Read more
BeOne Medicines
Technical Analysis Termsheets Terminal
Permalink
Tue, 26.08.2025       BeOne Medicines
US07725L1026

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8, 2025, with a fireside chat at 1:50 p.m. EDT. The live webcast of this event can be accessed from the investors section of the Company’s website...
Read more
BeOne Medicines
Technical Analysis Termsheets Terminal
Permalink
Mon, 25.08.2025       BeOne Medicines
US07725L1026

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it has entered into an agreement to sell its royalty rights on the worldwide sales, excluding China, of Amgen’s IMDELLTRA® (tarlatamab-dlle) for up to $950 million to Royalty Pharma (Nasdaq: RPRX). Under the terms of the agreement, BeOne will...
Read more
BeOne Medicines
Technical Analysis Termsheets Terminal
Permalink
Thu, 21.08.2025       BeOne Medicines
US07725L1026

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Commission has approved a new film-coated tablet formulation of BRUKINSA® (zanubrutinib) for all approved indications. "Developed to meet the real-world needs of patients, the new BRUKINSA tablet formulation aims to simplify...
Read more
BeOne Medicines
Technical Analysis Termsheets Terminal
Permalink
Thu, 31.07.2025       BeOne Medicines
US07725L1026

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Medicines Agency (EMA) has granted PRIority MEdicines (PRIME) designation to the Company’s investigational Bruton’s tyrosine kinase (BTK) degrader, BGB-16673, for the treatment of patients with Waldenstrom’s macroglobulinemia...
Read more
BeOne Medicines
Technical Analysis Termsheets Terminal
Permalink
Mon, 28.07.2025       BeOne Medicines
US07725L1026

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a positive opinion recommending approval of TEVIMBRA® (tislelizumab), in combination with platinum-containing chemotherapy as neoadjuvant tre...
Read more
BeOne Medicines
Technical Analysis Termsheets Terminal
Permalink
Wed, 16.07.2025       BeOne Medicines
US07725L1026

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its second quarter 2025 financial results on Wednesday, August 6, 2025 before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET. The live webcast of this even...
Read more
BeOne Medicines
Technical Analysis Termsheets Terminal
Permalink
Thu, 10.07.2025       BeOne Medicines
US07725L1026

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Commission has approved TEVIMBRA® (tislelizumab), in combination with gemcitabine and cisplatin, for the first-line treatment of adult patients with metastatic or recurrent nasopharyngeal carcinoma (NPC), not amenable to curat...
Read more
BeOne Medicines
Technical Analysis Termsheets Terminal
Permalink
Thu, 26.06.2025       BeOne Medicines
US07725L1026

In a significant showcase for investors, BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will announce major advancements to its industry-leading oncology pipeline during today’s investor R&D Day. The event comes at a pivotal moment for the Company, which has more than 40 clinical and commercial stage a...
Read more
BeOne Medicines
Technical Analysis Termsheets Terminal
Permalink
Wed, 25.06.2025       BeOne Medicines
US07725L1026

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a positive opinion recommending approval of a new film-coated tablet formulation of BRUKINSA® (zanubrutinib) for all approved indications. Th...
Read more
BeOne Medicines
Technical Analysis Termsheets Terminal
Permalink
Thu, 12.06.2025       BeOne Medicines
US07725L1026

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will present new clinical data from three cornerstone hematology assets at the European Hematology Association (EHA) Congress. Four oral presentations highlight the promising clinical activity of BeOne’s next-generation BCL2 inhibitor sonrotoclax, BTK protein...
Read more
BeOne Medicines
Technical Analysis Termsheets Terminal
Permalink
Wed, 11.06.2025       BeOne Medicines
US07725L1026

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved a new tablet formulation of BRUKINSA® (zanubrutinib) for all five approved indications. BRUKINSA remains the leader in new chronic lymphocytic leukemia (CLL) patient starts across al...
Read more
BeOne Medicines
Technical Analysis Termsheets Terminal
Permalink
Wed, 11.06.2025       BeOne Medicines
US07725L1026

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that it will host an Investor R&D Day in New York City and via webcast on June 26, 2025 at 8:30 am ET. John V. Oyler, Co-Founder, Chairman, and CEO of BeOne, along with the Company's leadership team and distinguished key opinion leaders, wi...
Read more
BeOne Medicines
Technical Analysis Termsheets Terminal
Permalink
Mon, 02.06.2025       BeOne Medicines
US07725L1026

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, announced new clinical data from its emerging breast cancer pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Poster presentations feature preliminary results of the dose escalation studies of two investigational molecules...
Read more
BeOne Medicines
Technical Analysis Termsheets Terminal
Permalink
Sat, 31.05.2025       BeOne Medicines
US07725L1026

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today will present new data from the Arm C and D cohorts of the pivotal, global Phase 3 SEQUOIA trial of BRUKINSA® (zanubrutinib). The findings underscore the strong and consistent efficacy of BRUKINSA across CLL patient types, including high-risk mutation sta...
Read more
BeOne Medicines
Technical Analysis Termsheets Terminal
Permalink
Tue, 27.05.2025       BeOne Medicines
US07725L1026

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company formerly known as BeiGene, Ltd., today announced its new name and redomiciliation to Switzerland are officially in effect, marking a significant milestone in the Company’s evolution. This press release features multimedia. View the full release here: https://w...
Read more
BeOne Medicines
Technical Analysis Termsheets Terminal
Permalink